CRISPR Therapeutics (CRSP) Insider Trading & Ownership $40.89 -1.73 (-4.06%) Closing price 04:00 PM EasternExtended Trading$41.29 +0.40 (+0.97%) As of 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRISPR Therapeutics (NASDAQ:CRSP) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.10%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$313,950.00Number OfInsiders Selling(Last 12 Months)3Amount OfInsider Selling(Last 12 Months)$5.71 M Get CRSP Insider Trade Alerts Want to know when executives and insiders are buying or selling CRISPR Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CRSP Insider Buying and Selling by Quarter Remove Ads CRISPR Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/11/2025James R KasingerGeneral CounselSell2,850$42.42$120,897.00 3/11/2025Julianne BrunoCOOSell1,198$42.42$50,819.16 3/11/2025Samarth KulkarniCEOSell9,973$42.42$423,054.66 2/26/2025John GreeneDirectorBuy7,000$44.85$313,950.00 2/19/2025Samarth KulkarniCEOSell18,360$55.20$1,013,472.00 12/2/2024Samarth KulkarniCEOSell15,000$55.10$826,500.00 11/11/2024Samarth KulkarniCEOSell30,000$55.62$1,668,600.00 10/14/2024James R KasingerGeneral CounselSell1,089$46.28$50,398.92 10/14/2024Samarth KulkarniCEOSell4,293$46.28$198,680.04 6/21/2024Julianne BrunoCOOSell3,366$56.09$188,798.94 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 4/15/2024Samarth KulkarniCEOSell19,582$59.91$1,173,157.62 (Data available from 1/1/2013 forward) CRSP Insider Trading Activity - Frequently Asked Questions Who is on CRISPR Therapeutics's Insider Roster? The list of insiders at CRISPR Therapeutics includes James R Kasinger, John Greene, Julianne Bruno, Raju Prasad, and Samarth Kulkarni. Learn more on insiders at CRSP. What percentage of CRISPR Therapeutics stock is owned by insiders? 4.10% of CRISPR Therapeutics stock is owned by insiders. Learn more on CRSP's insider holdings. Which CRISPR Therapeutics insiders have been buying company stock? The following insider purchased CRSP shares in the last 24 months: John Greene ($313,950.00). How much insider buying is happening at CRISPR Therapeutics? Insiders have purchased a total of 7,000 CRSP shares in the last 24 months for a total of $313,950.00 bought. Which CRISPR Therapeutics insiders have been selling company stock? The following insiders have sold CRSP shares in the last 24 months: James R Kasinger ($542,910.89), Julianne Bruno ($239,618.10), Raju Prasad ($256,159.56), and Samarth Kulkarni ($17,910,616.74). How much insider selling is happening at CRISPR Therapeutics? Insiders have sold a total of 315,121 CRISPR Therapeutics shares in the last 24 months for a total of $18,949,305.29 sold. CRISPR Therapeutics Key ExecutivesDr. Rodger Novak M.D. (Age 55)Founder, Chairman & Pres Dr. Samarth Kulkarni (Age 43)CEO & Director Compensation: $1.18M5 recent tradesDr. Lawrence Otto Klein Ph.D. (Age 40)Chief Operating Officer Compensation: $675kMr. James R. Kasinger (Age 50)Gen. Counsel & Sec. Compensation: $648.93k2 recent tradesMr. Shaun FoyFounderDr. Emmanuelle Marie CharpentierCo-Founder & Scientific Advisory Board MemberDr. Craig C. Mello Ph.D.Scientific Founder & Advisory Board MemberDr. Chad Cowan Ph.D.Scientific FounderDr. Matthew Porteus M.D. (Age 56)Ph.D., Scientific Founder & Advisory Board Member Dr. Daniel G. Anderson Ph.D.Scientific Founder & Advisory Board Member More Insider Trading Tools from MarketBeat Related Companies Moderna Insider Trades Neurocrine Biosciences Insider Trades Exelixis Insider Trades Bio-Techne Insider Trades Vaxcyte Insider Trades Repligen Insider Trades Halozyme Therapeutics Insider Trades Revolution Medicines Insider Trades Krystal Biotech Insider Trades ADMA Biologics Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles NVIDIA Insiders Sell: This Is What It Means for the Market Top 3 Insider Stock Buys in March—Are They Still Good in April?Grocery Outlet Insider and Institutional Buyers Signal BottomSentinelOne Insider Selling? Why Investors Should Stay Bullish 3 Companies Buying Back Stock—Why It Matters This page (NASDAQ:CRSP) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
